Pluri Inc

Pluri Inc a biotechnology company focuses on the development of placentabased cell therapy product candidates for the treatment of inflammatory muscle injuries and hematologic conditions The company develops placental expanded PLX based cell therapy products including PLXPAD that is in Phase III clinical trial for the muscle recovery following surgery for hip fracture and Phase III clinical trial for the treatment of steroidrefractory graft versus host disease in collaboration with Tel Aviv Sourasky Medical Center as well as completed a Phase II clinical trial for the treatment of acute respiratory distress syndrome associated with COVID19 and a Phase I clinical trial for incomplete recovery following bone marrow transplantation It also develops PLXR18 for incomplete hematopoietic recovery following hematopoietic cell transplantation and a solution for the treatment of acute radiation syndrome through its collaboration in the United States with the National Institutes of Health and the US Department of Defense The company was formerly known as Pluristem Therapeutics Inc and changed its name to Pluri Inc in July 2022 Pluri Inc was incorporated in 2001 and is based in Haifa Israel